What happened to Ohr Pharmaceutical's stock?
OHR Pharmaceutical's stock reverse split before market open on Monday, February 4th 2019. The 1-20 reverse split was announced on Wednesday, January 23rd 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 1st 2019.
Where is Ohr Pharmaceutical Inc located?
OHR Pharmaceutical, Inc. is headquartered in New York, New York. There is not enough analysis data for OHR Pharmaceutical. OHR Pharmaceutical has received 295 “outperform” votes.
Why is the stock market dropping?
That dropping is transient after investors recovered confidence in the market. “The most recent correction can be attributed to the level of uncertainty the market sees.” According to Rob Haworth, senior investment strategy director at U.S. Bank.
How were OHR Pharmaceutical's earnings last quarter?
OHR Pharmaceutical Inc (NASDAQ:OHRP) issued its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.20) ear...
When did OHR Pharmaceutical's stock split? How did OHR Pharmaceutical's stock split work?
OHR Pharmaceutical shares reverse split on Monday, February 4th 2019. The 1-20 reverse split was announced on Wednesday, January 23rd 2019. The num...
Who are OHR Pharmaceutical's key executives?
OHR Pharmaceutical's management team includes the following people: Dr. Jason Scott Slakter , CEO, Pres & Director (Age 61) Mr. Samuel Backenrot...
Who are some of OHR Pharmaceutical's key competitors?
Some companies that are related to OHR Pharmaceutical include CNS Pharmaceuticals (CNSP) , Midatech Pharma (MTP) , PainReform (PRFX) , Bellicum...
What other stocks do shareholders of OHR Pharmaceutical own?
Based on aggregate information from My MarketBeat watchlists, some companies that other OHR Pharmaceutical investors own include Actinium Pharmace...
What is OHR Pharmaceutical's stock symbol?
OHR Pharmaceutical trades on the NASDAQ under the ticker symbol "OHRP."
What is OHR Pharmaceutical's stock price today?
One share of OHRP stock can currently be purchased for approximately $1.02.
How much money does OHR Pharmaceutical make?
OHR Pharmaceutical (NASDAQ:OHRP) has a market capitalization of $2.89 million.
How many employees does OHR Pharmaceutical have?
OHR Pharmaceutical employs 3 workers across the globe.
How were OHR Pharmaceutical's earnings last quarter?
OHR Pharmaceutical Inc (NASDAQ:OHRP) announced its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.20) EPS for the quarter. View OHR Pharmaceutical's earnings history.
When did OHR Pharmaceutical's stock split? How did OHR Pharmaceutical's stock split work?
Shares of OHR Pharmaceutical reverse split on Monday, February 4th 2019. The 1-20 reverse split was announced on Wednesday, January 23rd 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 1st 2019.
Who are some of OHR Pharmaceutical's key competitors?
Some companies that are related to OHR Pharmaceutical include InMed Pharmaceuticals (INM), Bellicum Pharmaceuticals (BLCM), NovaBay Pharmaceuticals (NBY), Pasithea Therapeutics (KTTA), Mallinckrodt (MNKKQ), NLS Pharmaceutics (NLSP), Novelion Therapeutics (NVLNF), Hoth Therapeutics (HOTH), Abliva AB (publ) (NEVPF), REVERE BK LAURE/SH SH (REVB), Yumanity Therapeutics (YMTX), GeoVax Labs (GOVX), Xenetic Biosciences (XBIO), Trevi Therapeutics (TRVI) and Midatech Pharma (MTP). View all of OHRP's competitors..
What other stocks do shareholders of OHR Pharmaceutical own?
Based on aggregate information from My MarketBeat watchlists, some companies that other OHR Pharmaceutical investors own include Actinium Pharmaceuticals (ATNM), TherapeuticsMD (TXMD), Cytori Therapeutics (CYTX), Synergy Pharmaceuticals (SGYP), IVERIC bio (OPHT), Novavax (NVAX), Immunomedics (IMMU), OPKO Health (OPK), Dynavax Technologies (DVAX) and Energy Transfer (ET)..
What is OHR Pharmaceutical's stock symbol?
OHR Pharmaceutical trades on the NASDAQ under the ticker symbol "OHRP."
What is OHR Pharmaceutical's stock price today?
One share of OHRP stock can currently be purchased for approximately $1.33.
What is OHR Pharmaceutical's official website?
The official website for OHR Pharmaceutical is www.ohrpharmaceutical.com.
Signals & Forecast
There are mixed signals in the stock today. The Ohr Pharmaceuticals stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Support, Risk & Stop-loss
Ohr Pharmaceuticals finds support from accumulated volume at $1.31 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Is Ohr Pharmaceuticals stock A Buy?
Ohr Pharmaceuticals holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
About Ohr Pharmaceuticals
OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is OHR-102 eye drops, a novel therapeutic product, which could provide a non-invasive therapy to enhance vision outcomes.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Can Netflix Hold off Disney, Amazon, and HBO in the Streaming Wars?
Streaming video giant Netflix has come a long way from its early days of mailing physical copies of DVDs to its customers across the country.
Tech Stocks Roundup: Well-Known Value Investor Likes Google, Meta, Netflix
Check out the latest news and performance numbers from the top technology and FAANG/MAMAA stocks like Amazon, Apple, Microsoft, Intel, and more.
Disney World Ends a Big Perk: That May Be Good for Disney Stock
The company has steadily raised prices and taken away things from its theme park customers and they seem to keep coming.
How to Craft a Great Elevator Pitch (With Examples)
You never know who could be a potential customer or who knows someone who could be. A short, sweet “elevator pitch” tells the world who you are and what you do.
Peloton's Surprise Move May Kill Its 2022 Comeback Efforts
The connected fitness pioneer has struggled and its latest decision suggests that's likely to continue.
Walmart Plans to Sell Virtual Goods, Create Cryptocurrency and NFTs
Walmart files applications seeking trademarks for digital currency, software to manage cryptocurrency and other digital assets and for online retail services.
Consumer Spending Remains Strong, Says Mastercard CEO
'We continue to see benefits from accumulated savings and an increasing push toward digital,' said Michael Miebach.
Key Points
Ree Automotive is collaborating with a major automotive supplier to create a mobility-as-a-service offering.
NASDAQ: REE
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
What happened
Shares of Israeli-based electric vehicle (EV) technology company Ree Automotive ( REE -6.90% ) sank Tuesday as the company filed for a major common-share sale. As of 3 p.m. EDT today, Ree shares were tumbling 35%.
So what
Ree Automotive began trading publicly in July 2021 after merging with a special purpose acquisition company (SPAC). Ree designs and manufactures mobility platforms for EVs and offers several different models for EV companies to build their models based on Ree's platforms.
Now what
The 30 million shares represent the full amount that the initial private investment in public equity (PIPE) purchased in the SPAC deal. They also amount to about 10% of current shares outstanding.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.
